Proton Therapy Market Size, Share, Growth, Trends, and Global Industry Analysis: By Type of System (Single Room System and Multi-Room System), By Application (Paediatric Cancer, Head and Neck Cancer, Prostate Cancer, Lung Cancer, Gastro-Intestinal Cancer, Brain Cancer, and Others), By End-User (Hospitals, Radiotherapy Centers and Others) and Region Forecast 2020-2031

Proton Therapy Market size was valued at US$ 805.0 million in 2024 and is expected to reach US$ 1,326.8 million by 2031, growing at a significant CAGR of 7.4% from 2025-2031. Proton therapy is also known as proton beam radiation therapy. Proton is a positively charged particle, and in high energy levels, protons can destroy cancer cells. Proton therapy is a non-invasive procedure in which proton radiation is used to treat cancer. It is a type of external beam radiation therapy, that painlessly delivers radiation through the skin from outside of the body. Cancer significantly influences society globally and in the United States, increasing the market growth. The statistics on cancer depict the disease's impact on society across time.

For instance, according to the data updated by the American Cancer Society in January 2023, in the US, breast cancer is the most prevalent cancer to affect women. It represents one in three, or 30%, of all newly diagnosed female cancers in the nation each year. As per the same source, in women, by the end of 2023, there will be about 297,790 new instances of invasive breast cancer and 55,720 new cases of ductal carcinoma in situ (DCIS). For the treatment of cancer, proton therapy may be prescribed alone or along with other treatments such as surgery, chemotherapy, general radiation therapy, and or immunotherapy.

However, the application of new, cutting-edge technologies poses ethical, economical, and practical concerns. High costs associated with Quality Assurance (QA), Quality Control (QC), capital investment, and operating expenses are significant concerns and may restrain the market growth. Also, the high expense of sophisticated radiation and proton therapy equipment presents a major hurdle for market. These high costs may make radiation solutions less accessible to healthcare providers and create obstacles to new entrants seeking to enter the market as they also necessitate highly skilled personnel and top-notch QA/QC programs due to limited treatment modification opportunities.

Key Developments

• In 2023, IBA signs contract with partner CGN Medical Technology for the installation of a Proteus®PLUS system in China
• In 2022, IBA Radiopharma Solutions, being a medical technology company and key provider of proton therapy solutions for the treatment of cancer, announced a contract with Eugene M. & Christine E. Lynn Cancer Institute of Boca Raton Regional Hospital. This contract with Baptist Health South Florida will see the installation of its compact proton therapy system, ProteusONE.
• In 2021, The collaboration of Tractebel and IBA worldwide with increased support to the agreement and increased designing of the proton therapy and improved infrastructures.